Exbio — Research products — Antibodies — CD and related antigens — Anti-Hu CD158agh PE-Cy™7

Anti-Hu CD158agh PE-Cy™7

Regulatory status

RUO

Antigen

CD158agh

Clone

HP-MA4

Format

PE-Cy™7

Reactivity

Human

Application

FC (QC tested)

Excitation laser

blue (488 nm)

Variant

100 tests

T7-775-T100

In stock

275.00 USD

Variant

100 tests

T7-775-T100

In stock

275.00 USD

Contact distributor

Product details

Description

Images

References

SDS download

Isotype

Mouse IgG2b kappa

Specificity

The mouse monoclonal antibody HP-MA4 recognizes an extracellular epitope of CD158 isoforms KIR2DL1 (CD158a), KIR2DS5 (CD158g), KIR2DS1 (CD158h), and KIR2DS3. It does not recognize the isoforms CD158b1,d,f,i,j.

Application

FC (QC tested)

Application details

Flow cytometry: The reagent is designed for analysis of human blood cells using 4 μl reagent / 100 μl of whole blood or 10⁶ cells in a suspension. The content of a vial (0.4 ml) is sufficient for 100 tests.

Reactivity

Human

Immunogen

Human NK cell line LB2

Preparation

Purified antibody is conjugated with activated tandem dye of R-phycoerythrin-cyanine 7 (PE-Cy™7) under optimum conditions and unconjugated antibody and free fluorochrome are removed by size-exclusion chromatography.

Formulation

Stabilizing phosphate buffered saline (PBS), pH 7.4, 15 mM sodium azide

Storage and handling

Store at 2-8°C. Protect from prolonged exposure to light. Do not freeze.

The product is intended For Research Use Only. Diagnostic or therapeutic applications are strictly forbidden. Products shall not be used for resale or transfer to third parties either as a stand-alone product or as a manufacture component of another product without written consent of EXBIO Praha, a.s. EXBIO Praha, a.s. will not be held responsible for patent infringement or any other violations of intellectual property rights that may occur with the use of the products. Orders for all products are accepted subject to the Term and Conditions available at www.exbio.cz. EXBIO, EXBIO Logo, and all other trademarks are property of EXBIO Praha, a.s.

Cy™ and CyDye™ are registered trademarks of Cytiva.

Other names

KIR2DL1, NKAT, KIR2DS1, KIR2DS3, NKAT7, KIR2DS5, NKAT9, CD158g, CD158h, CD158a

Antigen description

Killer cell immunoglobulin-like receptors (KIRs) are polymorphic transmembrane glycoproteins expressed by natural killer cells and subsets of T cells. They are classified by the number of extracellular immunoglobulin domains (2D or 3D) and by whether they have a long (L) or short (S) cytoplasmic domain. KIR proteins with the long cytoplasmic domain (such as CD158a / KIR2DL1) transduce inhibitory signals upon ligand binding via an immune tyrosine-based inhibitory motif (ITIM), while KIR proteins with the short cytoplasmic domain (such as CD158g / KIR2DS5, CD158h / KIR2DS1, or KIR2DS3) lack the ITIM motif and instead associate with the TYRO protein tyrosine kinase binding protein to transduce activating signals. The ligands for CD158 isoforms are subsets of MHC class I molecules.

Entrez Gene ID 3805

UniProt ID Q99706

Flow cytometry surface staining pattern of human peripheral whole blood stained using anti-human CD158agh (HP-MA4) PE-Cy™7 antibody (4 μl reagent / 100 μl of peripheral whole blood).

Flow cytometry multicolor surface staining pattern of human peripheral blood mononuclear cells using anti-human CD3 (UCHT1) APC antibody (10 μl reagent / 100 μl of peripheral whole blood) and anti-human CD158agh (HP-MA4) PE-Cy™7 antibody (4 μl reagent / 100 μl of peripheral whole blood).

Separation of human CD158agh positive CD3 negative lymphocytes (red-filled) from CD158agh negative CD3 positive lymphocytes (black-dashed) in flow cytometry analysis (surface staining) of human peripheral whole blood stained using anti-human CD158agh (HP-MA4) PE-Cy™7 antibody (4 μl reagent / 100 μl of peripheral whole blood).

Product specific references:

Wiernik A, Foley B, Zhang B, Verneris MR, Warlick E, Gleason MK, Ross JA, Luo X, Weisdorf DJ, Walcheck B, Vallera DA, Miller JS: Targeting natural killer cells to acute myeloid leukemia in vitro with a CD16 x 33 bispecific killer cell engager and ADAM17 inhibition. Clin Cancer Res. 2013 Jul 15;19(14):3844-55
PubMed